The phase 3 ALBAN trial tested atezolizumab plus BCG in BCG-naïve patients with high-risk, non-muscle-invasive bladder cancer (NMIBC).

PlGF cutoff <100 pg/mL demonstrated 100 percent sensitivity and specificity at 20 to 24 weeks of gestation for early-onset preeclampsia.

(HealthDay News) — Primary care physicians (PCPs) spend an average of 61.8 hours per week caring for a patient panel, according to a study published online Oct. 21 in the Annals of Internal Medicine.

(HealthDay News) — Macrovascular infiltration and spikes in circulating tumor cell (CTC) clusters are associated with cancer mortality, according to a study published online Oct. 16 in Nature Medicine ...

ASN’s Kidney Week 2025 is happening November 5-9, 2025 at the George R. Brown Convention Center in Houston, Texas.

(HealthDay News) — More than one in five young adults report using cannabis or alcohol to get to sleep, according to a research letter published online Oct. 13 in JAMA Pediatrics.

Smaller declines seen in early-stage cancer diagnosis during COVID-19 pandemic in adults aged 18 to 44 years, men, those with high comorbidity burden.

The phase 3 POTOMAC trial tested durvalumab added to BCG in patients with high-risk non-muscle-invasive bladder cancer (NMIBC).

Adding durvalumab to induction and maintenance with Bacillus Calmette–Guérin (BCG) can improve disease-free survival in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer, data ...

Prevalence increased to 68.6 percent with new criteria, which include anthropometric measures such as waist circumference, waist-to-hip ratio, waist-to-height ratio.

Immune checkpoint inhibitors have shown efficacy in other HPV-related cancers, so a phase 2 trial tested avelumab treatment for locally advanced or metastatic penile cancer.

Adding EV and pembrolizumab to surgical treatment can improve outcomes in MIBC patients who are ineligible for cisplatin, data suggest.